welcome to cyprotexcloe® screencloe® selectcloe® predict

Parallel artificial membrane permeability assay (PAMPA)

The parallel artificial membrane permeability assay is one of our Cloe Screen portfolio of in vitro ADME screening services. Cyprotex deliver consistent, high quality data with cost-efficiency that comes from a highly automated approach.

Parallel artificial membrane permeability assay (PAMPA)

  • The Parallel Artificial Membrane Permeability Assay (PAMPA) is used as an in vitro model of passive, transcellular permeation.
  • PAMPA avoids the complexities of active transport, allowing test compounds to be ranked based on a simple permeability property alone.
  • The ability of this assay to evaluate permeability over a large pH range is valuable for an early understanding how new oral compounds might be absorbed across the entire gastrointestinal tract.
‘The parallel artificial membrane permeability assay (PAMPA), first introduced by Kansy et al., has been widely used in the pharmaceutical industry as a
high throughput permeability assay to predict oral absorption.’
1Di L., Kerns E.H., Fan K., McConnell O.J., and Carter GT. (2003) Eur J Med Chem 38; 223-232
Protocol +
Data +
Q&A +
References

1 Di L et al. (2003) Eur J Med Chem 38; 223-232.
2 Wohnsland F and Faller B.J. (2001) Med Chem 44; 923-930.

3 Di L and Kerns EH. (2003) Current Opinion in Chemical Biology 7; 402-408

PAMPA

Download a copy of the product sheet

Cloe® is a registered trade mark owned by Cyprotex PLC

careerscontactlegalprivacy
This website was last updated
on 29th July 2010
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.